Oritavancin: A Long-Acting Antibacterial Lipoglycopeptide

Abstract

Oritavancin is a new lipoglycopeptide antibacterial agent with an exceptionally long terminal half-life and a rapid bactericidal effect. Multiple mechanisms of action lead to a broad activity against Gram-positive bacteria, such as staphylococci, streptococci and enterococci, including methicillin-resistant Staphylococcus aureus. Its long terminal half-life allows for single-dose treatment of acute bacterial skin and skin structure infections. Oritavancin was found to be safe and effective in treating acute bacterial skin and skin structure infections in adults and it is currently approved in the USA and in Europe for this indication. Unfortunately, data for other indications are lacking. Here, we review chemistry, microbiology, pharmacology, efficacy and tolerability of oritavancin.

KEYWORDS:

• antibiotic
• antimicrobial
• glycopeptide
• Gram-positive
• lipoglycopeptide
• long-acting
• single dose
• skin-soft-tissue infection

Disclaimer

In addition to the peer review process, with the author's consent, the manufacturer of the product discussed in this article was given the opportunity to review the manuscript for factual accuracy. Changes were made by the author at their discretion and based on scientific or editorial merit only. The author maintained full control over the manuscript, including content, wording and conclusions.

Financial & competing interests disclosure

AJ Kaasch has received grants from the Bundesministerium für Bildung und Forschung (BMBF), and the Deutsche Forschungsgemeinschaft (DFG), payments for lectures from BD Biosciences, Biomérieux, MSD Sharp & Dohme, Limbach Gruppe SE, and ViiV Healthcare, and travel support from Janssen-Cilag. H Seifert has received grants or research support from the Bundesministerium für Bildung und Forschung (BMBF), Germany, the German Center for Infection Research (DZIF), Basilea, Novartis and Pfizer, has been a consultant for Astellas, AstraZeneca, Basilea, Cubist, Novartis, Pfizer, Tetraphase, and The Medicines Company, and has received payments for lectures from MSD, Novartis and Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

AJ Kaasch has received grants from the Bundesministerium für Bildung und Forschung (BMBF), and the Deutsche Forschungsgemeinschaft (DFG), payments for lectures from BD Biosciences, Biomérieux, MSD Sharp & Dohme, Limbach Gruppe SE, and ViiV Healthcare, and travel support from Janssen-Cilag. H Seifert has received grants or research support from the Bundesministerium für Bildung und Forschung (BMBF), Germany, the German Center for Infection Research (DZIF), Basilea, Novartis and Pfizer, has been a consultant for Astellas, AstraZeneca, Basilea, Cubist, Novartis, Pfizer, Tetraphase, and The Medicines Company, and has received payments for lectures from MSD, Novartis and Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.